Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
48.67
USD
|
-1.64%
|
|
-2.66%
|
-25.03%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
4,252
|
4,582
|
3,410
|
3,739
|
2,830
|
-
|
-
|
Enterprise Value (EV)
1 |
4,088
|
4,406
|
3,084
|
3,623
|
2,749
|
2,715
|
2,729
|
P/E ratio
|
323
x
|
507
x
|
-116
x
|
-2,164
x
|
-53.2
x
|
344
x
|
100
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
30.4
x
|
16.5
x
|
8.89
x
|
7.57
x
|
4.73
x
|
4.01
x
|
3.43
x
|
EV / Revenue
|
29.3
x
|
15.9
x
|
8.04
x
|
7.34
x
|
4.59
x
|
3.85
x
|
3.31
x
|
EV / EBITDA
|
206
x
|
288
x
|
-147
x
|
433
x
|
-118
x
|
109
x
|
41.7
x
|
EV / FCF
|
-76.4
x
|
372
x
|
-129
x
|
116
x
|
-529
x
|
183
x
|
66.7
x
|
FCF Yield
|
-1.31%
|
0.27%
|
-0.78%
|
0.86%
|
-0.19%
|
0.55%
|
1.5%
|
Price to Book
|
21.5
x
|
19.2
x
|
8.23
x
|
7.93
x
|
6.71
x
|
6.51
x
|
5.94
x
|
Nbr of stocks (in thousands)
|
48,711
|
50,205
|
53,653
|
57,590
|
58,138
|
-
|
-
|
Reference price
2 |
87.29
|
91.27
|
63.56
|
64.92
|
48.67
|
48.67
|
48.67
|
Announcement Date
|
3/9/21
|
2/23/22
|
2/27/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
51.13
|
139.7
|
277
|
383.5
|
493.6
|
598.6
|
705.4
|
824.7
|
EBITDA
1 |
-
|
19.8
|
15.3
|
-20.98
|
8.364
|
-23.24
|
24.97
|
65.36
|
EBIT
1 |
-
|
18.42
|
10.84
|
-28.1
|
-2.371
|
-42.38
|
4.881
|
36.26
|
Operating Margin
|
-
|
13.19%
|
3.92%
|
-7.33%
|
-0.48%
|
-7.08%
|
0.69%
|
4.4%
|
Earnings before Tax (EBT)
1 |
-
|
13.79
|
10.68
|
-26.18
|
4.246
|
-44.05
|
7.326
|
35.52
|
Net income
1 |
-
|
13.79
|
9.84
|
-29.27
|
-1.636
|
-49.84
|
8.215
|
28.58
|
Net margin
|
-
|
9.87%
|
3.55%
|
-7.63%
|
-0.33%
|
-8.33%
|
1.16%
|
3.47%
|
EPS
2 |
-0.1400
|
0.2700
|
0.1800
|
-0.5500
|
-0.0300
|
-0.9143
|
0.1417
|
0.4860
|
Free Cash Flow
1 |
-
|
-53.52
|
11.84
|
-23.92
|
31.22
|
-5.2
|
14.8
|
40.9
|
FCF margin
|
-
|
-38.32%
|
4.27%
|
-6.24%
|
6.32%
|
-0.87%
|
2.1%
|
4.96%
|
FCF Conversion (EBITDA)
|
-
|
-
|
77.42%
|
-
|
373.23%
|
-
|
59.26%
|
62.58%
|
FCF Conversion (Net income)
|
-
|
-
|
120.34%
|
-
|
-
|
-
|
180.17%
|
143.11%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/21/20
|
3/9/21
|
2/23/22
|
2/27/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
83.22
|
86.75
|
92.74
|
96.2
|
107.8
|
116.2
|
119
|
126.4
|
132.1
|
143.2
|
143.8
|
151.4
|
160.1
|
167.3
|
170.1
|
EBITDA
1 |
3.444
|
-1.983
|
-8.095
|
-8.018
|
-4.001
|
-2.365
|
0.63
|
4.285
|
3.131
|
-12.56
|
-9.878
|
-4.707
|
-0.2325
|
2.86
|
7.329
|
EBIT
1 |
1.746
|
-3.082
|
-9.328
|
-9.798
|
-5.891
|
-5.338
|
-1.51
|
2.113
|
-0.319
|
-17.18
|
-14.95
|
-10.14
|
-6.698
|
-2.73
|
0.3203
|
Operating Margin
|
2.1%
|
-3.55%
|
-10.06%
|
-10.18%
|
-5.47%
|
-4.6%
|
-1.27%
|
1.67%
|
-0.24%
|
-12%
|
-10.39%
|
-6.7%
|
-4.18%
|
-1.63%
|
0.19%
|
Earnings before Tax (EBT)
1 |
1.681
|
-3.129
|
-8.935
|
-9.313
|
-4.808
|
-1.194
|
3.024
|
5.59
|
-3.176
|
-16.09
|
-15.04
|
-9.695
|
-5.123
|
-2.014
|
1.384
|
Net income
1 |
1.107
|
-3.129
|
-10.19
|
-10.15
|
-5.798
|
-2.218
|
2.085
|
3.162
|
-4.667
|
-24.2
|
-14.35
|
-9.829
|
-5.943
|
-1.936
|
0.9287
|
Net margin
|
1.33%
|
-3.61%
|
-10.98%
|
-10.55%
|
-5.38%
|
-1.91%
|
1.75%
|
2.5%
|
-3.53%
|
-16.9%
|
-9.98%
|
-6.49%
|
-3.71%
|
-1.16%
|
0.55%
|
EPS
2 |
0.0200
|
-0.0600
|
-0.1900
|
-0.1900
|
-0.1100
|
-0.0400
|
0.0400
|
0.0500
|
-0.0800
|
-0.4200
|
-0.2629
|
-0.1800
|
-0.1086
|
-0.0280
|
0.0150
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/23/22
|
5/4/22
|
8/3/22
|
11/2/22
|
2/27/23
|
5/3/23
|
8/2/23
|
11/1/23
|
2/28/24
|
4/30/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
164
|
176
|
326
|
115
|
80.8
|
115
|
101
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-53.5
|
11.8
|
-23.9
|
31.2
|
-5.2
|
14.8
|
40.9
|
ROE (net income / shareholders' equity)
|
-
|
17.1%
|
4.48%
|
-8.92%
|
2.27%
|
-4.7%
|
3.59%
|
9.55%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
1.7%
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-96.15
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
4.070
|
4.750
|
7.720
|
8.190
|
7.250
|
7.480
|
8.200
|
Cash Flow per Share
2 |
-
|
0.0400
|
-
|
-0.2600
|
0.6300
|
0.7100
|
-0.1000
|
-
|
Capex
1 |
-
|
5.46
|
-
|
9.95
|
4.71
|
7.7
|
8.8
|
10.7
|
Capex / Sales
|
-
|
3.91%
|
-
|
2.59%
|
0.95%
|
1.29%
|
1.25%
|
1.3%
|
Announcement Date
|
2/21/20
|
3/9/21
|
2/23/22
|
2/27/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
48.67
USD Average target price
64.4
USD Spread / Average Target +32.32% Consensus |
1st Jan change
|
Capi.
|
---|
| -25.03% | 2.83B | | -24.88% | 7.32B | | +7.04% | 6.66B | | +15.10% | 5.5B | | -17.86% | 4.88B | | +14.96% | 4.1B | | -20.83% | 3.89B | | +44.01% | 2.31B | | +2.10% | 2.07B | | +9.75% | 1.97B |
Medical Equipment
|